RE:RE:Medipharm Labs Big Win alleyesonme wrote: Yes, lower revenue products are being replaced with higher revenue offerings, this year pharmaceutical API (dronabinol) comprises 10% of revenue, New B2B contracts signed for increases from almost nothing to close to 900k last quarter, costs have systematically dropped two years straight. I'm pleased with the focus on international medica and API, Canadian rec market is a joke, the gov is killing the industry, Labs paid 1.8m in excise tax this year so far, meanwhile the largest players simply aren't paying excise tax with 100's of millions owing and no repercussions.
I would agree that the last Q or so highlighted some positive things.
But, when those positive things had essentially nothing to do with the massive catalysts that the business had apparently been waiting on, then something doesn't jive. There was never any indication that B2B or Drob was going to represent a significant uptick and thus I don't think anyone should take those lines as sustaining. Unless we get a NR that states a nice juicy recurring Drob PO, then it's just manna from heaven.
When you look at the investor deck, the catalysts they presented have either long gone or have been long silent. That's not a good look when your strategic outlook doesn't align with your tactical business.